Correction of clerical error

IXICO plc

22 October 2024

 

22 October 2024

IXICO PLC

("IXICO" or the "Company")

Correction of clerical error

IXICO plc (AIM: IXI), has become aware of a clerical error in resolutions 1 and 3 (the "Resolutions") as set out in the notice of general meeting accompanying the circular sent to shareholders dated 9 October 2024 (the "Circular") convening a general meeting for 25 October 2024 (the "General Meeting"). The Resolutions seek shareholder authority to issue the New Ordinary Shares in connection with the Fundraising. The aggregate nominal value of shares referred to in the Resolutions should have been £447,368.42 rather than £42,500. This corrected figure is consistent with the figures relating to the Fundraising set out elsewhere in the Circular.

In accordance with its articles of association the Company intends to propose additional ordinary resolutions at the General Meeting to amend the Resolutions and correct this error.

Shareholders do not need to take any further action in relation to the business to be conducted at the Meeting.

Defined terms used in this announcement have the meanings given to them in the Circular unless otherwise stated.

For further information please contact:

IXICO plc	[phone]
Bram Goorden, Chief Executive Officer Grant Nash, Chief Financial Officer
Cavendish Capital Markets Limited  (Nominated adviser and sole broker)	[phone]
Giles Balleny / Dan Hodkinson (Corporate Finance)
Nigel Birks (Life Sciences Specialist Sales)
Harriet Ward (Corporate Broking)
Michael F Johnson / Tamar Cranford Smith (Sales)

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.

IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.

More information is available on www.IXICO.com and follow us on X (formerly Twitter) @IXICOnews

 

END